|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 为表面的胃肠的瘤的移动的内视镜的 submucosal 解剖: 技术评论显示文摘 Endoscopic submucosal dissection (ESD) is now the most common endoscopic treatment in Japan for intramucosal gastrointestinal neoplasms (non-metastatic). ESD is an invasive endoscopic surgical procedure, requiring extensive knowledge, skill, and specialized equipment. ESD starts with evaluation of the lesion, as accurate assessment of the depth and margin of the lesion is essential. The devices and strategies used in ESD vary, depending on the nature of the lesion. Prior to the procedure, the operator must be knowledgeable about the treatment strategy(ies), the device(s) to use, the electrocautery machine settings, the substances to inject, and other aspects. In addition, the operator must be able to manage complications, should they arise, including immediate recognition of the complication(s) and its treatment. Finally, in case the ESD treatment is not successful, the operator should be prepared to apply alternative treatments. Thus, adequate knowledge and training are essential to successfully perform ESD. | Noriaki Matsui Kazuya Akahoshi Kazuhiko Nakamura Eikichi Ihara Hiroto Kita | 2012 | World Journal of Gastrointestinal Endoscopy2012，4，4： | 34 |
| 2 | Apoptosis and non-alcoholic fatty liver diseases显示文摘The number of patients with nonalcoholic fatty liver diseases(NAFLD) including nonalcoholic steatohepatitis(NASH), has been increasing. NASH causes cirrhosis and hepatocellular carcinoma(HCC) and is one of the most serious health problems in the world. The mechanism through which NASH progresses is still largely unknown. Activation of caspases, Bcl-2 family proteins, and c-Jun N-terminal kinase-induced hepatocyte apoptosis plays a role in the activation of NAFLD/NASH. Apoptotic hepatocytes stimulate immune cells and hepatic stellate cells toward the progression of fibrosis in the liver through the production of inflammasomes and cytokines. Abnormalities in glucose and lipid metabolism as well as microbiota accelerate these processes. The production of reactive oxygen species, oxidative stress, and endoplasmic reticulum stress is also involved. Cell death, including apoptosis, seems very important in the progression of NAFLD and NASH. Recently, inhibitors of apoptosis have been developed as drugs for the treatment of NASH and may prevent cirrhosis and HCC. Increased hepatocyte apoptosis may distinguish NASH from NAFLD, and the improvement of apoptosis could play a role in controlling the development of NASH. In this review, the association between apoptosis and NAFLD/NASH are discussed. This review could provide their knowledge, which plays a role in seeing the patients with NAFLD/NASH in daily clinical practice. | Tatsuo Kanda Shunichi Matsuoka Motomi Yamazaki Toshikatsu Shibata Kazushige Nirei Hiroshi Takahashi Tomohiro Kaneko Mariko Fujisawa Teruhisa Higuchi Hitomi Nakamura Naoki Matsumoto Hiroaki Yamagami Masahiro Ogawa Hiroo Imazu Kazumichi Kuroda Mitsuhiko Moriyama | 2018 | World Journal of Gastroenterology2018，24，25： | 32 |
| 3 | Myeloid immunosuppression and immune checkpoints in the tumor microenvironment显示文摘Tumor-promoting inflammation and the avoidance of immune destruction are hallmarks of cancer.While innate immune cells,such as neutrophils,monocytes,and macrophages,are critical mediators for sterile and nonsterile inflammation,persistent inflammation,such as that which occurs in cancer,is known to disturb normal myelopoiesis.This disturbance leads to the generation of immunosuppressive myeloid cells,such as myeloid-derived suppressor cells(MDSCs)and tumor-associated macrophages(TAMs).Due to their potent suppressive activities against effector lymphocytes and their abundance in the tumor microenvironment,immunosuppressive myeloid cells act as a major barrier to cancer immunotherapy.Indeed,various therapeutic approaches directed toward immunosuppressive myeloid cells are actively being tested in preclinical and clinical studies.These include antiinflammatory agents,therapeutic blockade of the mobilization and survival of myeloid cells,and immunostimulatory adjuvants.More recently,immune checkpoint molecules expressed on tumor-infiltrating myeloid cells have emerged as potential therapeutic targets to redirect these cells to eliminate tumor cells.In this review,we discuss the complex crosstalk between cancer-related inflammation and immunosuppressive myeloid cells and possible therapeutic strategies to harness antitumor immune responses. | Kyohei Nakamura Mark J.Smyth | 2020 | Cellular & Molecular Immunology2020，17，1： | 31 |
| 4 | One-step palliative treatment method for obstructive jaundice caused by unresectable malignancies by percutaneous transhepatic insertion of an expandable metallic stent显示文摘瞄准:为了描述包含可扩充的金属的经皮的 transhepatic 插入的一个简单一步舞方法,在妨碍的黄疸的治疗使用的斯滕特氏印模膏(他们) 由 unresectable 恶意引起了。方法:由于 unresectable 恶意与妨碍的黄疸诊断的十四个病人在学习被包括。在这些病人的恶意是很先进的癌或老年的结果。经皮的 transhepatic 胆管造影术在 ultrasonographic 指导下面被执行。在有一个内部金属性的指南的一根导管是先进的进十二指肠以后,一他们被放在胆总管,在一个点之间在到肝的核的 Vater 和入口的乳头状的小突起以外的 1 厘米。在用就一个单身者跨越距离是困难的情况中他们,另外的斯滕特氏印模膏被放。一根排水导管在地方被离开充当一把止血钳子。在胆汁郁积和斯滕特氏印模膏明显的分辨率被证实以后,导管被移开 2 或 3 d 过程以后。结果:EMS 的一步舞插入与 24.4 min 的一过程平均数时间在所有病人被完成。从要求了 2 他们的病人, 4 需要一过程时间超过 30 min。导管的移动的吝啬的时间过程以后是 2.3 d。所有病人与 7.8 瞬间的一吝啬的后续时间死于恶意。没有 stent 相关的复杂并发症或斯滕特氏印模膏阻塞被遇到。结论:他们的一步舞经皮的 transhepatic 插入是为决定胆汁的阻塞和罐头有效地改进病人生命的质量的一个简单过程。 | Hiroshi Yoshida Yasuhiro Mamada Nobuhiko Taniai Yoshiaki Mizuguchi Tetsuya Shimizu Shigeki Yokomuro Takayuki Aimoto Yoshiharu Nakamura Eiji Uchida Yasuo Arima Manabu Watanabe Eiichi Uchida Takashi Tajiri | 2006 | World Journal of Gastroenterology2006，12，15： | 28 |
| 5 | Cell transplantation therapies for spinal cord injury focusing on induced pluripotent stem cells显示文摘在为 Shinya Yamanaka 和约翰·格尔登爵士授于的生理学或药由 2012 诺贝尔奖金刺激了,对导致的 pluripotent 茎(iPS ) 有增加的兴趣在医药科学的细胞和 reprograming 技术。当 iPS 房间被期望打开以房间治疗和再生药在生物医学的科学提供庞大的机会的一个新时代时,为 iPS 的安全相关的担心基于房间的房间治疗应该在 iPS 房间的临床的申请以前被解决。在这评论,为用神经干细胞的针的绳索损害(SCI ) 的房间治疗的现出症状之前的潜的调查在 vivo 源于 iPS 房间,和他们的安全问题,被构画出。我们也希望讨论策略因为第一个人为 SCI 病人 iPS 落后于基于房间的房间治疗。 | Masaya Nakamura Hideyuki Okano | 2013 | Cell Research2013，23，1： | 22 |
| 6 | Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis显示文摘AIM: to evaluate the effectiveness of probiotic therapy for suppressing relapse in patients with inactive ulcerative colitis(UC).METHODS: Bio-Three tablets, each containing 2 mg of lactomin(Streptococcus faecalis T-110), 10 mg of Clostridium butyricum TO-A, and 10 mg of Bacillus mesentericus TO-A, were used as probiotic therapy.Sixty outpatients with UC in remission were randomly assigned to receive 9 Bio-Three tablets/day(BioThree group) or 9 placebo tablets/day(placebo group)for 12 mo in addition to their ongoing medications.Clinical symptoms were evaluated monthly or on the exacerbation of symptoms or need for additional medication. Fecal samples were collected to analyze bacterial DNA at baseline and 3-mo intervals. Terminal restriction fragment length polymorphism and cluster analyses were done to examine bacterial components of the fecal microflora.RESULTS: Forty-six patients, 23 in each group,completed the study, and 14 were excluded. The relapse rates in the Bio-Three and placebo groups were respectively 0.0% vs 17.4% at 3 mo(P = 0.036), 8.7%vs 26.1% at 6 mo(P = 0.119), and 21.7% vs 34.8%(P = 0.326) at 9 mo. At 12 mo, the remission rate was 69.5% in the Bio-Three group and 56.6% in the placebo group(P = 0.248). On cluster analysis of fecal flora, 7 patients belonged to cluster Ⅰ, 32 to cluster Ⅱ,and 7 to cluster Ⅲ.CONCLUSION: Probiotics may be effective formaintaining clinical remission in patients with quiescent UC, especially those who belong to cluster Ⅰ on fecal bacterial analysis. | Yasushi Yoshimatsu Akihiro Yamada Ryuichi Furukawa Koji Sono Aisaku Osamura Kentaro Nakamura Hiroshi Aoki Yukiko Tsuda Nobuo Hosoe Nobuo Takada Yasuo Suzuki | 2015 | World Journal of Gastroenterology2015，21，19： | 21 |
| 7 | 直肠上皮瘤行内镜黏膜下层切除术 | Fujishiro M. Yahagi N. Nakamura M. 程妍 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，0，10： | 21 |
| 8 | Precision surgical approach with lymph-node dissection in early gastric cancer显示文摘The gravest prognostic factor in early gastric cancer is lymph-node metastasis,with an incidence of about 10% overall. About two-thirds of early gastric cancer patients can be diagnosed as node-negative prior to treatment based on clinicpathological data. Thus, the tumor can be resected by endoscopic submucosal dissection. In the remaining third, surgical resection is necessary because of the possibility of nodal metastasis. Nevertheless, almost all patients can be cured by gastrectomy with D1+ lymph-node dissection. Laparoscopic or robotic gastrectomy has become widespread in East Asia because perioperative and oncological safety are similar to open surgery. However, after D1+ gastrectomy,functional symptoms may still result. Physicians must strive to minimize postgastrectomy symptoms and optimize long-term quality of life after this operation.Depending on the location and size of the primary lesion, preservation of the pylorus or cardia should be considered. In addition, the extent of lymph-node dissection can be individualized, and significant gastric-volume preservation can be achieved if sentinel node biopsy is used to distinguish node-negative patients.Though the surgical treatment for early gastric cancer may be less radical than in the past, the operative method itself seems to be still in transition. | Shinichi Kinami Naohiko Nakamura Yasuto Tomita Takashi Miyata Hideto Fujita Nobuhiko Ueda Takeo Kosaka | 2019 | World Journal of Gastroenterology2019，25，14： | 21 |
| 9 | Neoadjuvant chemotherapy for locally advanced cervical cancer显示文摘Neoadjuvant chemotherapy followed by surgery(NCS) has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy(NAC) used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Many randomized controlled trials(RCTs) have examined the long-term prognosis of NCS compared to primary surgery, but the utility of NCS remains uncertain. The advent of concurrent chemoradiotherapy(CCRT) has markedly improved the outcome of radiotherapy(RT), and CCRT is now used as a standard method in many cases of advanced bulky cervical cancer. NCS gives a better treatment outcome than radiation therapy alone, but it is important to verify that NCS gives a similar or better outcome compared to CCRT. | Takashi Iwata Azumi Miyauchi Yukako Suga Hiroshi Nishio Masaru Nakamura Akiko Ohno Nobumaru Hirao Tohru Morisada Kyoko Tanaka Hiroki Ueyama Hidemichi Watari Daisuke Aoki | 2016 | Chinese Journal of Cancer Research2016，28，2： | 20 |
| 10 | Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis显示文摘Nonalcoholic fatty liver disease(NAFLD) including nonalcoholic steatohepatitis(NASH) is globally increasing and has become a world-wide health problem. Chronic infection with hepatitis B virus or hepatitis C virus(HCV) is associated with hepatic steatosis. Viral hepatitis-associated hepatic steatosis is often caused by metabolic syndrome including obesity,type 2 diabetes mellitus and/or dyslipidemia. It has been reported that HCV genotype 3 exerts direct metabolic effects that lead to hepatic steatosis. In this review,the differences between NAFLD/NASH and viral hepatitis-associated steatosis are discussed. | Yuki Haga Tatsuo Kanda Reina Sasaki Masato Nakamura Shingo Nakamoto Osamu Yokosuka | 2015 | World Journal of Gastroenterology2015，21，46： | 20 |
| 11 | Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer显示文摘AIM:To investigate whether gene methylation in the peritoneal fluid (PF) predicts peritoneal recurrence in gastric cancer patients.METHODS: The gene methylation of CHFR (checkpoint with forkhead and ring finger domains), p16, RUNX3 (runt-related transcription factor 3), E-cadherin, hMLH1 (mutL homolog 1), ABCG2 (ATP-binding cassette, sub-family G, member 2) and BNIP3 (BCL2/adenovirus E1B 19 kDa interacting protein 3) were analyzed in 80 specimens of PF by quantitative methylation-specific polymerase chain reaction (PCR). Eighty patients were divided into 3 groups; Group A (n=35):the depth of cancer invasion was less than the muscularis propria; Group B (n=31): the depth of cancer invasion was beyond the muscularis propria. Both group A and B were diagnosed as no cancer cells in peritoneal cytology and histology; Group C (n=14): disseminated nodule was histologically diagnosed or cancer cells were cytologically defi ned in the peritoneal cavity.RESULTS: The positive rates of methylation in CHFR, E-cadherin and BNIP3 were significantly different among the 3 groups and increased in order of group A, B and C (0%,0% and 21% in CHFR, P<0.05; 20%, 45% and 50% in E-cadherin, P<0.05;26%,35% and 71% in BNIP3, P<0.05). In addition, the multigene methylation rate among CHFR, E-cadherin and BNIP3 was correlated with group A, B and C (9%,19% and 57%, P<0.001). Moreover, the prognosis was analyzed in group B, excluding 3 patients who underwent a non-curative resection. Two of the 5 patients with multigene methylation showed peritoneal recurrence after surgery, while those without or with a single gene methylation did not experience recurrence (P<0.05).CONCLUSION: This study suggested that gene methylation in the PF could detect occult neoplastic cells in the peritoneum and might be a risk factor for peritoneal metastasis. | Masatsugu Hiraki Yoshihiko Kitajima Seiji Sato Jun Nakamura Kazuyoshi Hashiguchi Hirokazu Noshiro Kohji Miyazaki | 2010 | World Journal of Gastroenterology2010，16，3： | 20 |
| 12 | Improving recognition of hepatic perivascular epithelioid cell tumor:Case report and literature review显示文摘A 58-year-old man presented with the chief complaint of abdominal bloating and was incidentally found to have a liver tumor.As diagnostic imaging studies could not rule out malignancy,the patient underwent partial resection of segment 3 of the liver.The lesion pathologically showed eosinophilic proliferation,in addition to immunohistochemical positivity for human melanoma black 45 and Melan-A,thereby leading to the diagnosis of a hepatic perivascular epithelioid cell tumor(PEComa).A PEComa arising from the liver is relatively rare.Moreover,the name ‘PEComa' has not yet been widely recognized,and the same disease entity has been called epithelioid angiomyolipoma(EAML),further diminishing the recognition of PEComa.In addition,PEComa imaging findings mimic those of malignant liver tumors,and clinically,this tumor tends to enlarge.Therefore,a PEComa is difficult to diagnose.We conducted a systematic review of PEComa and EAML cases and discuss the results,including findings useful for differentiating perivascular epithelioid cell tumors from malignant liver tumors. | Toshiya Maebayashi Katsumi Abe Takuya Aizawa Masakuni Sakaguchi Naoya Ishibashi Osamu Abe Tadatoshi Takayama Hisashi Nakayama Shunichi Matsuoka Kazushige Nirei Hitomi Nakamura Masahiro Ogawa Masahiko Sugitani | 2015 | World Journal of Gastroenterology2015，21，17： | 20 |
| 13 | Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules显示文摘煽动性的肠疾病(IBD ) 的病原学还没被澄清了,非明确地减少发炎和免疫的抑制免疫力的代理人为 IBD 在常规治疗被使用了。证据显示在 IBD 的内脏的粘膜免疫的 dysregulation 引起煽动性的 cytokines 和受动器白血球的交通国王的生产过剩进肠,因此导致不受管束的肠的发炎。在 IBD 的致病的理解的如此的最近的进展创造了明确地禁止涉及煽动性的串联的分子的新奇生物制品疗法的一个最近的趋势。为如此的处理的主要目标是煽动性的 cytokines 和他们的受体,和粘附分子。妄想的 anti-TNF-alpha 单音的同种细胞的抗体, infliximab,为 CD 成为了标准治疗,它也是可能的为 UC 有益。几 anti-TNF 试剂被开发了,但是他们中的大多数似乎不象 infliximab 一样有效。人性化的 anti-TNF 单音的同种细胞的抗体, adalimumab 可能为输了的病人的治疗是有用的应答的海角或发达不耐到 infliximab。对 IL-12 p40 和 IL-6 受体的抗体能是为 IBD 的其他的新 anti-cytokine 治疗。Anti-interferon-gamma 和 anti-CD25 治疗被开发,但是这些代理人的利益还没被建立了。进肠的白细胞移行的选择堵住似乎是一条好途径。对 alpha4 integrin 和 alpha4beta7 integrin 的抗体为 IBD 显示出利益。细胞间的粘附分子 1 的 Antisense oligonucleotide (ICAM-1 ) 可能为 IBD 是有效的。如此的混合物的临床的试用最近也被报导了或当前是在进行之中的。在这篇文章,我们为 IBD 考察如此的新奇生物制品疗法的功效和安全。 | Kazuhiko Nakamura Kuniomi Honda Takahiro Mizutani Hirotada Akiho Naohiko Harada | 2006 | World Journal of Gastroenterology2006，12，29： | 18 |
| 14 | Radiation therapy for portal venous invasion by hepatocellular carcinoma显示文摘AIM: To clarify the efficacy and safety of three-dimensional conformal radiotherapy (3-D CRT) for this disease and to specify patient subgroups suitable for this treatment.METHODS: Fifty-two patients with HCC received PVI-targeted radiation therapy from January 1995 through December 2003. Portal venous invasion (PVI) was found in the second or lower order branches of the portal vein in 6 patients, in the first branch in 24 patients and in the main trunk in 22 patients. Child classifications of liver function before radiation therapy were A, B, and C for 19, 24 and 2 patients, respectively. All patients received three-dimensional conformal radiotherapy with a total dose ranging from 39 to 60 Gy (57.0 Gy in average).RESULTS: Overall survival rates at 1, 2, 3, 4, and 5 years were 45.1%, 25.3%, 15.2%, 10.1%, and 5.1%, respectively. Univariate analysis revealed that Child status, the number of tumor foci, tumor type,transcatheter arterial embolization (TAE) after radiation therapy were statistically significant prognostic factors.Multivariate analysis showed that the number of tumor foci and TAE after radiation therapy were statistically significant.CONCLUSION: The results of this study strongly suggest the efficacy of 3-D CRT as treatment for PVI in HCC. 3-D CRT is recommended in combination with postradiation TAE for PVI of HCC with 5 tumor foci or less in the liver and with Child A liver function. | Keiichi Nakagawa Hideomi Yamashita Kenshiro Shiraishi Naoki Nakamura Masao Tago Hiroshi Igaki Yoshio Hosoi Shuichiro Shiina Masao Omata Masatoshi Makuuchi Kuni Ohtomo | 2005 | World Journal of Gastroenterology2005，11，46： | 14 |
| 15 | Bacteremia in hemodialysis patients显示文摘Infection is a common complication and is the second leading cause of death in hemodialysis patients. The risk of bacteremia in hemodialysis patients is 26-fold higher than in the general population, and 1/2-3/4 of the causative organisms of bacteremia in hemodialysis patients are Gram-positive bacteria. The ratio of resistant bacteria in hemodialysis patients compared to the general population is unclear. Several reports have indicated that hemodialysis patients have a higher risk of methicillin-resistant Staphylococcus aureus infection. The most common site of infection causing bacteremia is internal prostheses; the use of a hemodialysis catheter is the most important risk factor for bacteremia. Although antibiotic lock of hemodialysis catheters and topical antibiotic ointment can reduce catheter-related blood stream infection(CRBSI), their use should be limited to necessary cases because of the emergence of resistant organisms. Systemic antibiotic administration and catheter removal is recommended for treating CRBSI, although a study indicated the advantages of antibiotic lock and guidewire exchange of catheters over systemic antibiotic therapy. An infection control bundle recommended by the Center for Disease Control and Prevention succeeded in reducing bacteremia in hemodialysis patients with either a catheter or arteriovenous fistula. Appropriate infection control can reduce bacteremia in hemodialysis patients. | Masashi Suzuki Nobuhiko Satoh Motonobu Nakamura Shoko Horita George Seki Kyoji Moriya | 2016 | World Journal of Nephrology2016，5，6： | 14 |
| 16 | Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies显示文摘Dear Editor,Mutations in the β-globin gene,the essential component of adult hemoglobin(HbA;a2p2),results in either a production of aberrant sickle hemoglobin(HbS)leading to sickle cell disease(SCD)or an insufficient β-globin synthesis leading to β-thalassemia.These two major forms of β-hemoglobinopathies cause impaired erythropoiesis and life-threatening anemia.Clinical evidence has suggested that reaaivation of fetal γ-globin(HBG)gene expression which is normally silenced after birth by certain genetic mutations can ameliorate the clinical course of β-hemoglobinopathies. | Liren Wang Linxi Li Yanlin Ma Handan Hu Qi Li Yang Yang Wenbang Liu Shuming Yin Wei Li Bin Fu Ryo Kurita Yukio Nakamura Mingyao Liu Yongrong Lai Dali Li | 2020 | Cell Research2020，30，3： | 14 |
| 17 | Retroperitoneal fibrosis associated with immunoglobulin G4-related disease显示文摘Retroperitoneal fibrosis is a rare disease characterized by the development of inflammation and fibrosis in the soft tissues of the retroperitoneum and other abdominal organs.Retroperitoneal fibrosis can be of 2 types:idiopathic and secondary.The recently advocated concept and diagnostic criteria of immunoglobulin G4(IgG4)-related disease,derived from research on autoimmune pancreatitis(AIP),has led to widespread recognition of retroperitoneal fibrosis as a condition caused by IgG4-related disease.We now know that previously diagnosed idiopathic retroperitoneal fibrosis includes IgG4-related disease;however,the actual prevalence is unclear.Conversely,some reports on AIP suggest that retroperitoneal fibrosis is concurrently found in about 10% of IgG4-related disease.Because retroperitoneal fibrosis has no specific symptoms,diagnosis is primarily based on diagnostic imaging(computed tomography and magnetic resonance imaging),which is also useful in evaluating the effect of therapy.Idiopathic retroperitoneal fibrosis can occur at different times with other lesions of IgG4-related disease including AIP.Thus,the IgG4 assay is recommended to diagnose idiopathic retroperitoneal fibrosis.High serum IgG4 levels should be treated and monitored as a symptom of IgG4-related disease.The first line of treatment for retroperitoneal fibrosis is steroid therapy regardless of its cause.For patients with concurrent AIP,i.e.,IgG4-related retroperitoneal fibrosis,the starting dose of steroid is usually 30-40 mg/d.The response to steroid therapy is generally favorable.In most cases,the pancreatic lesion and retroperitoneal fibrosis improve after the initial treatment.However,the epidemiology,treatment for recurring retroperitoneal fibrosis,and long-term prognosis are still largely unknown.Further analysis of such cases and research are necessary. | Nao Fujimori Tetsuhide Ito Hisato Igarashi Takamasa Oono Taichi Nakamura Yusuke Niina Masayuki Hijioka Lingaku Lee Masahiko Uchida Ryoichi Takayanagi | 2013 | World Journal of Gastroenterology2013，19，1： | 14 |
| 18 | 远端血管保护装置Guard Wire在急性心肌梗死急诊介入治疗中的应用显示文摘目的 评价GuardWire在急性心肌梗死 (AMI)急诊介入治疗时应用的价值。方法 连续观察 4 8例AMI急诊介入治疗并应用了GuardWire的患者 ,记录术中心电图变化及血流情况等 ,分析该装置的操作、造影和手术成功率 ,以及住院期间和术后 30d内的心血管事件发生率。结果 操作成功率、造影成功率和手术成功率均为 10 0 %。远端球囊阻塞时间平均 (8 1± 6 8)min ,所有患者均能良好耐受。 93 8%的患者吸引出肉眼可见的血栓 /斑块碎片 ,术中未出现因远端血管阻塞而引起的血液动力学或心电图、症状变化 ,未出现远端血管栓塞或无血流现象。住院期间和术后 30d内的心血管事件发生率均为 0。结论 该装置容易操作 ,可安全地应用于冠状动脉系统 ,有效防止AMI急诊介入治疗中可能出现的远端血管栓塞。 | 黄铮 陈红武 Osamu Katoh Shigeru Nakamura | 2003 | 中华心血管病杂志2003，31，11： | 14 |
| 19 | Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome显示文摘The pathogenesis of irritable bowel syndrome (IBS) is considered to be multifactorial and includes psychosocial factors, visceral hypersensitivity, infection, microbiota and immune activation. It is becoming increasingly clear that low-grade inflammation is present in IBS patients and a number of biomarkers have emerged. This review describes the evidence for low-grade inflammation in IBS and explores its mechanism with particular focus on gastrointestinal motor dysfunction. Understanding of the immunological basis of the altered gastrointestinal motor function in IBS may lead to new therapeutic stra- tegies for IBS. | Hirotada Akiho Eikichi Ihara Kazuhiko Nakamura | 2010 | World Journal of Gastrointestinal Pathophysiology2010，1，3： | 13 |
| 20 | First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype显示文摘AIM: To evaluate the effect of first line esomeprazole(EPZ)-based triple therapy on Helicobacter pylori(H. pylori) eradication.METHODS: A total of 80 Japanese patients with gastritis who were diagnosed as positive for H. pylori infection by endoscopic biopsy-based or ^(13)C-urea breath tests were included in this study. The average age of the patients was 57.2 years(male/female, 42/38). These patients were treated by first-line eradication therapy with EPZ 40 mg/d, amoxicillin 1500 mg/d, and clarithromycin 400 mg/d for 7 d. All drugs were given twice per day. Correlations between H. pylori eradication, CYP2C19 genotype, and serum pepsinogen(PG) level were analyzed. This study was registered with the UMIN Clinical Trials Registry(UMIN000009642).RESULTS: The H. pylori eradication rates by EPZbased triple therapy evaluated by intention-to-treat and per protocol were 67.5% and 68.4%, respectively, which were similar to triple therapies with other first-generation proton pump inhibitors(PPIs). The eradication rates in three different CYP2C19 genotypes, described as extensive metabolizer(EM), intermediate metabolizer, and poor metabolizer, were 52.2%, 72.1%, and 84.6%, respectively. The H. pylori eradication rate was significantly lower in EM than non-EM(P < 0.05). The serum PG?Ⅰ?level and PG?Ⅰ/Ⅱ ratio were significantly increased after eradication of H. pylori(P < 0.01), suggesting that gastric atrophy was improved by H. pylori eradication. Thus, first-line eradication by EPZbased triple therapy for patients with H. pylori-positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with other firstgeneration PPIs in the Japanese population.CONCLUSION: The results from this study suggest that there is no advantage to EPZ-based triple therapy on H. pylori eradication compared to other firstgeneration PPIs. | Yoshimasa Saito Hiroshi Serizawa Yukako Kato Masaru Nakano Masahiko Nakamura Hidetsugu Saito Hidekazu Suzuki Takanori Kanai | 2015 | World Journal of Gastroenterology2015，21，48： | 13 |
您所在的机构暂未开通此部分的功能，请联系管理员